{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:00:26Z","timestamp":1785222026363,"version":"3.55.0"},"reference-count":10,"publisher":"Baishideng Publishing Group Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Pediatr"],"abstract":"<jats:p>This letter discusses the pilot study by Kotb et al  published in World Journal of Clinical Pediatrics , which identifies significantly reduced serum cytochrome P450 1A2 (CYP1A2) levels in neonates with biliary atresia and neonatal hepatitis compared to healthy controls. While these findings highlight a potential role for detoxification mechanisms in neonatal cholestasis, critical methodological issues regarding the interpretation of results warrant attention. The primary concern is the causality dilemma; it is crucial to distinguish between an innate \u2018defect\u2019 (congenital deficiency) and \u2018downregulation\u2019 (secondary suppression). Low CYP1A2 levels may be a secondary consequence of systemic inflammation rather than an inherent susceptibility factor. Furthermore, the reliance on enzyme-linked immunosorbent assay for protein abundance lacks the resolution of functional activity assays. Future research should integrate single-cell multi-omics and gut-metabolite signaling to decode the complexity of the hepatic microenvironment.<\/jats:p>","DOI":"10.5409\/wjcp.118192","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:08:04Z","timestamp":1780416484000},"source":"Crossref","is-referenced-by-count":0,"title":["Letter to the Editor: Causality dilemma of cytochrome P450 1A2 reduction in neonatal cholestasis"],"prefix":"10.5409","volume":"15","author":[{"given":"H\u00fcseyin","family":"Yi\u011fit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkerim","family":"G\u00f6ko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonay","family":"G\u00f6ko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000548519"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5409\/wjcp.v15.i1.113478"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141059"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018747"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00330-2"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.270"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20240332"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280691"}],"container-title":["World Journal of Clinical Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2219-2808\/full\/v15\/i3\/118192.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2219-2808\/full\/v15\/i3\/118192.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:28:35Z","timestamp":1785220115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2219-2808\/full\/v15\/i3\/118192.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":10,"journal-issue":{"issue":"3"},"alternative-id":["118192"],"URL":"https:\/\/doi.org\/10.5409\/wjcp.118192","relation":{},"ISSN":["2219-2808"],"issn-type":[{"value":"2219-2808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}